FDA approves Eliquis on week 600 Cluster 2 reps eliminated

Discussion in 'Pfizer' started by Anonymous, Dec 28, 2012 at 6:03 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    A stroke-preventing pill from Pfizer Inc. PFE -0.99% and Bristol-Myers Squibb Co. BMY -0.75% won approval from U.S. health regulators Friday, setting the stage for a fierce fight among drug makers to replace the widely used bloodthinner warfarin.
     

  2. Anonymous

    Anonymous Guest

    Happened after market close dumb ass!!
     
  3. Anonymous

    Anonymous Guest

    Wonder how many contract reps we will have selling this.
     
  4. Anonymous

    Anonymous Guest

    BMS has it in their rules that no contract reps can sell it. Lets remember they let not only us go but nearly all the P4s too. They let 700 go.
     
  5. Anonymous

    Anonymous Guest

    The market never sleeps. Wake up, Bud Fox.
     
  6. Anonymous

    Anonymous Guest

    shows how useless primary care reps are needed in the new age of EMR/CPOE world.
     
  7. Anonymous

    Anonymous Guest

    Can anyone tell me why they're laying off so many reps NOW, when we need reps to sell Eliquis? This doesn't make sense to me.
     
  8. Anonymous

    Anonymous Guest

    Younger, better looking, lower paid, more ignorant (if that were possible) reps available.
     
  9. Anonymous

    Anonymous Guest

    My guess is that they want to produce as much revenue as possible with the least amount of cost. It's just like any other business. We have our work cut out for us. Many doctors have been burned by pradaxa and xalreto. And we don't even have all the indications we want/need.
     
  10. Anonymous

    Anonymous Guest

    timing was impeccable. Already writing down expectations ahead of launch. They knew the FDA approval was forthcoming in 2012.